Remember meForgot password?
    Log in with Twitter
| Press Release

Wired News – Cellectar Biosciences to Present Results from Phase-1 Study of CLR 124 Uptake in Brain Tumors at the World Congress of the World Federation of Nuclear Medicine and Biology

Stock Monitor: Achaogen Post Earnings Reporting

LONDON, UK / ACCESSWIRE / March 08, 2018 / has just released a free research report on Cellectar Biosciences, Inc. (NASDAQ: CLRB) ("Cellectar"). If you want access to this report all you need to do is sign up now by clicking the following link as the Company's latest news hit the wire. On March 06, 2018, the Company announced that it will present results from a Phase 1 study with 124I-CLR1404, also known as CLR 124, demonstrating an ability to cross the blood brain barrier and achieve uptake in brain tumors at the 12th World Congress of the World Federation of Nuclear Medicine and Biology, taking place April 20-24, 2018 in Melbourne, Australia. Register today and get access to over 1,000 Free Research Reports by joining our site below: is currently working on the research report for Achaogen, Inc. (NASDAQ: AKAO), which also belongs to the Healthcare sector as the Company Cellectar Biosciences. Do not miss out and become a member today for free to access this upcoming report at: is focused on giving you timely information and the inside line on companies that matter to you. This morning, Cellectar Biosciences most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

Cellectar to Initiate Phase-1 Pediatric Study Pediatric High-Grade Gliomas and Malignant Brain Tumors

James Caruso, Chief Executive Officer of Cellectar, mentioned that the Phase-1 data suggest that CLR124 is able to cross the blood-brain barrier and enter brain tumor cells, an important property for both diagnostic and therapeutic compounds. This may have positive read-through for CLR 131, the Company's analogous molecule that uses I-131 for therapy. James added that the Company plans to initiate a Phase-1 pediatric study in cancers including pediatric high-grade gliomas and malignant brain tumors in the near future.

PLE Molecules Provide Greater Than 20-Fold Increase in delivery of PDC to Cancerous Cells

Cellectar has engineered new Phospholipid Drug Conjugates™ (PDC) compounds specifically for improved tumor targeting. The Company's research has demonstrated that with a variety of payloads the phospholipid ether (PLE) molecules provide greater than 20-fold increase in delivery of the PDC to cancerous cells compared to normal cells. This mechanism provides an opportunity to potentially increase efficacy and reduce the off-target impact and associated side effects of many chemotherapeutics.

PDCs Ability to Achieve Strong Uptake in Brain Tumors Underscores the Potential of Cellectar's PDC Platform Technology

John Friend, MD, Chief Medical Officer of Cellectar, stated that earlier studies have demonstrated avid uptake of CLR 124 and CLR 131 in a broad spectrum of preclinical tumor models. The Company's preclinical research corroborated with these clinical results in human brain tumors.

John added that the demonstration of the PDCs ability to access the brain with a systemically-administered compound and achieve strong uptake in brain tumors, underscores the potential of the Company's PDC platform technology to selectively deliver oncologic payloads to highly restricted compartments within the body.

Cellectar Filed IND for Phase-1 Trial of CLR 131 in Pediatric Cancers

In December 2017, the Company filed an Investigational New Drug (IND) application with the Division of Oncology at the US Food and Drug Administration (FDA) for a proposed Phase-1 study of CLR 131 in children and adolescents with select rare and orphan designated cancers.

Phase-1 Clinical Study of CLR 131 in Pediatric Brain Cancers

The Phase-1 clinical trial of CLR 131 is an open-label, sequential-group, dose-escalation study to evaluate the safety and tolerability of a single intravenous administration of CLR 131 in up to 30 children and adolescents with cancers including neuroblastoma, sarcomas, lymphomas (including Hodgkin's lymphoma) and malignant brain tumors. Secondary objectives of the study are to identify the recommended Phase-2 dose of CLR 131 and to determine preliminary antitumor activity (treatment response) of CLR 131 in children and adolescents.

About CLR 124

CLR 124 is Cellectar's cancer-selective alkyphosphocholine analog, or Phospholipid Drug ConjugateTM, radiolabeled with iodine-124. This molecule is analogous to the Company's lead asset CLR 131, an investigational radioiodinated PDC cancer therapy that exploits the tumor-targeting properties of the Company's proprietary PLEs and PLE analogs to selectively deliver radiation to malignant tumor cells, thus minimizing radiation exposure to normal tissues.

About Phospholipid Drug Conjugates™

Cellectar's product candidates are built upon a cancer cell-targeting delivery and retention platform of optimized PDCs. The PDC platform selectively delivers diverse oncologic payloads to cancerous cells and cancer stem cells, including hematologic cancers and solid tumors. This selective delivery allows the payloads' therapeutic window to be modified, which may maintain or enhance drug potency while reducing the number and severity of adverse events. This platform takes advantage of a metabolic pathway utilized by all tumor cell types in all cell cycle stages.

About Cellectar Biosciences, Inc.

Founded in 1996 and headquartered in Madison, Wisconsin, Cellectar Biosciences is a pharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The Company is developing phospholipid drug conjugates (PDCs), designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells.

Stock Performance Snapshot

March 07, 2018 - At Wednesday's closing bell, Cellectar Biosciences' stock was slightly up 0.41%, ending the trading session at $1.22.

Volume traded for the day: 266.94 thousand shares, which was above the 3-month average volume of 263.93 thousand shares.

Stock performance in the last month – up 6.55%

After yesterday's close, Cellectar Biosciences' market cap was at $18.98 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.5% at the end of the session.


Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:


Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors